

**O I P E**

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Assistant Commissioner For Patents, Washington, D.C. 20231 on April 1, 2002.

APR 12 2002

Bara M. Kendall	43.709
Name of Attorney	Registration No.

*Dara M. Kendall*  
Signature of Attorney

Case 7070

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In the Application of

D. N. RUBINGH ET AL. : Confirmation No. 3865

Serial No. 09/646,984 : Group Art Unit 1652

Filed September 25, 2000 : Examiner William W. Moore

For SERINE PROTEASE VARIANTS HAVING AMINO ACID DELETIONS AND  
SUBSTITUTIONS

**AMENDMENT**

Assistant Commissioner for Patents

Washington, D.C. 20231

Dear Sir:

This amendment is responsive to the Office Action dated March 8, 2002. Please consider the following amendment and remarks.

**REMARKS**

The Examiner has indicated that the above-referenced application contains sequence disclosures that are encompassed by the definitions for nucleotide and/or amino acid sequences set forth in 37 C.F.R. 1.82(a)(1) and (a)(2), requiring the Applicants' compliance with the requirements of 37 C.F.R. 1.821 through 1.825. Applicants respectfully request reconsideration of the instant application in light of the following. Applicants submit herewith Sequence Listings for the above-referenced application, both in hard copy and electronic (computer-readable) form, and a Statement Under 37 C.F.R. 1.821(f) affirming the equivalence of the hard copy and electronic form Sequence Listings. It is believed that the aforementioned submissions constitute compliance of the instant application with the requirements of 37 C.F.R. 1.821 through 1.825. Thus, examination of the above-referenced application under 35 U.S.C. §§ 131 and 132 is respectfully requested.

TECH CENTER 1600/2900  
APR 16 2002

**RECEIVED**